ADCT vs NBIX · rev $40.1M vs P/E 45, rev $1.77B
ADC Therapeutics SA (ADCT) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ADCT currently screens at market cap $141.2M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ADCT and NBIX stock pages for the full models.
Not investment advice.